ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Aprepitant

Also written as “aprepitant”, “MK0869, aprepitant” and “Aprepitant Injection”.

Its studies are mostly in Depressive Disorder, Major · Vomiting · Nausea · Postoperative Nausea and Vomiting · Pruritus, led by 7 companies.

Drug pageAprepitant: every studyMany companies study it; this page follows only the 27 they lead. All 128 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 21, 200427 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only210 open or runningphase 4since Sep 21, 2004May 2, 2002none ahead
CSPC Pharmaceutical Groupits history only11 open or runningphase 3since Jul 17, 2024Jul 17, 2024none ahead
Lahore Medical Research Center, LLPits history only10 open or runningphase 3since Feb 23, 2024Feb 23, 2024none ahead
LEO Pharma10 open or runningphase 2since Sep 18, 2013Sep 18, 2013none ahead
Nuformix Technologiesits history only10 open or runningphase 1since Mar 20, 2019Mar 20, 2019none ahead
Ono Pharmaceuticalits history only10 open or runningphase 2since Sep 13, 2005Sep 13, 2005none ahead
Qilu Pharmaceuticalits history only10 open or runningphase 3since Apr 10, 2025Apr 10, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of LEO Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 18, 2013First study: phase 2 study in PruritusFirst studyNCT01963793 · 20 enrolled · Germany

TargetBeta

TACR1 →read by rule
“Neurokinin 1 receptor antagonist”ChEMBL 37, by rule

Other programs on TACR1

ProgramCompanyFurthest phaseStudies
elinzanetantruleBayerphase 324
tradipitantruleVanda Pharmaceuticalsphase 319
fosnetupitantruleHelsinn Healthcarephase 32
HRS5580Jiangsu HengRui Medicinephase 22

Studies

The one study LEO Pharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01963793Pruritus · Germany2CompletedJul 201420

How it is read

Names in the registry

  • “aprepitant”, 8 entries
  • “Aprepitant”, 4 entries
  • “MK0869, aprepitant”, 4 entries
  • “Aprepitant Injection”, 2 entries
  • “Aprepitant 125 mg”, 2 entries

Codes read as this program: MK0869.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.